Instrument Inactif

Autres langues Apptix ASA Oslo Bors

Actions

NO0010123060

Equipement et technologie médicale avancés

Autres langues

13/07	Carasent (Q2 Review): Positive momentum in several key areas
13/07	Carasent: Initiatives in Infosolutions the biggest highlight – Q2 review
10/07	Carasent (Q2 Initial take): Solid Q2 in line with expectations
10/07	Carasent: Solid report with continued ARR strength – Q2 initial
10/07	Carasent () : interim report Q2 2026
10/07	Carasent AB (publ) – interim report Q2 2026
10/07	Carasent AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
03/07	Carasent () : Invitation to presentation of Q2 2026 results
03/07	Carasent AB (publ) – Invitation to presentation of Q2 2026 results
24/06	Carasent: Infosolutions adds another layer to the story – Q2 preview
09/06	Carasent completes the acquisition of Infosolutions
09/06	Carasent AB (OM:CARA) acquired Infosolutions Sverige Ab for an enterprise value of approximately SEK 120 million.
29/05	Change in the number of shares and votes in Carasent AB (publ)
27/04	Carasent AB (OM:CARA) agreed to acquire Infosolutions Sverige Ab for an enterprise value of approximately SEK 120 million.
27/04	Carasent: Broadening with lab solution in Sweden
27/04	Carasent: Announces acquisition of Infosolutions
27/04	Carasent to Buy Infosolutions Sverige in SEK115 Million Deal
27/04	Carasent buys Infosolutions, strengthens position in Swedish private healthcare
27/04	Carasent acquires Infosolutions and strengthens its position in Swedish private healthcare
20/04	Annual General Meeting in Carasent AB (publ)
15/04	Carasent (Q1 review): Medsum momentum and German milestone
15/04	Carasent: Focus on recurring revenue – Q1 review
14/04	Carasent (Q1 initial take): Strong ARR, but profitability below expectations on higher costs and softer consulting
14/04	Carasent AB Reports Earnings Results for the First Quarter Ended March 31, 2026
14/04	Carasent: Miss on headline but recurring revenue strong – Q1 initial